<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127954</url>
  </required_header>
  <id_info>
    <org_study_id>3110-306-002</org_study_id>
    <nct_id>NCT05127954</nct_id>
  </id_info>
  <brief_title>Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)</brief_title>
  <official_title>A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a common neurological disorder typically characterized by attacks of throbbing,&#xD;
      moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light&#xD;
      and sound. Migraine is extremely common and disabling in children. The purpose of this study&#xD;
      is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of&#xD;
      migraine in children and adolescents.&#xD;
&#xD;
      Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and&#xD;
      adolescents (aged 6-17 years) with a history of migraine will be enrolled. Participants who&#xD;
      completed the lead-in Study 3110-305-002, as well as those who were placebo responders and&#xD;
      screen failed, will be eligible to enroll into this study. Around 1200 participants will be&#xD;
      enrolled in the study at approximately 103 sites in the United States.&#xD;
&#xD;
      Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any&#xD;
      intensity per month. There will be an option to take a second dose of study intervention&#xD;
      (identical to initial dose), or rescue medication, starting 2 hours after the initial dose.&#xD;
      The study duration will be up to 54 weeks.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The safety and tolerability of the treatment will be checked by medical assessments,&#xD;
      blood tests, checking for adverse events and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2021</start_date>
  <completion_date type="Anticipated">May 5, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>up to 54 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Up to 54 Weeks</time_frame>
    <description>12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Potentially Clinically Significant Vital Sign Parameters</measure>
    <time_frame>Up to 54 Weeks</time_frame>
    <description>Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Potentially Clinically Significant lab values</measure>
    <time_frame>Up to 54 Weeks</time_frame>
    <description>Percentage of participants with abnormal change in clinical laboratory test results like hematology will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of with Participants with Suicidal Ideation or Suicidal Behavior</measure>
    <time_frame>Up to 54 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Tanner staging score</measure>
    <time_frame>Up to 54 Weeks</time_frame>
    <description>Tanner's staging is used to assess growth and pubertal development.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From baseline in Behavior Rating Inventory of Executive Function (BRIEF 2) questionnaire</measure>
    <time_frame>up to 54 weeks</time_frame>
    <description>The BRIEF 2 is an 86-item questionnaire assessing executive function. It consists of 2 indexes, Behavioral Regulation and Metacognition, which are then used to calculate an overall composite score. Higher scores indicate more executive difficulties</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Adolescents Ubrogepant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 17 will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Ubrogepant Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 11 will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubrogepant</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Adolescents Ubrogepant Dose A</arm_group_label>
    <arm_group_label>Children Ubrogepant Dose B</arm_group_label>
    <other_name>Ubrelvy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completers of the lead-in Study 3110-305-002 (in the main study or PK cohort) or those&#xD;
             who screen failed due to being placebo responders.&#xD;
&#xD;
          -  Demonstrated an acceptable degree of compliance with study procedures in the lead-in&#xD;
             study and who, in the investigator's clinical judgment, did not experience an AE that&#xD;
             may indicate an unacceptable safety risk for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that&#xD;
             is on the list of prohibited concomitant medications that cannot be discontinued or&#xD;
             switched to an allowable, alternative medication at Visit 1.&#xD;
&#xD;
          -  An ECG with clinically significant abnormalities at Visit 1 as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Clinically significant abnormalities in physical examination at Visit 1, as determined&#xD;
             by the investigator.&#xD;
&#xD;
          -  Significant risk of self-harm, based on clinical interview and responses on the&#xD;
             C-SSRS, or of harm to others in the opinion of the investigator; participants must be&#xD;
             excluded if they report suicidal ideation with intent, with or without a plan (ie,&#xD;
             Type 4 or 5 on the C-SSRS), or report suicidal behavior at Visit 1&#xD;
&#xD;
          -  Any medical or other reason (eg, unlikely to adhere to the study procedures, keep&#xD;
             appointments, or is planning to relocate during the study) that, in the investigator's&#xD;
             opinion, might indicate that the participant is unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rehabilitation &amp; Neurological Services /ID# 240054</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805-4046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Trials - Saraland /ID# 239448</name>
      <address>
        <city>Saraland</city>
        <state>Alabama</state>
        <zip>36571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners /ID# 238979</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group /ID# 233422</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center /ID# 238967</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center /ID# 239135</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunwise Clinical Research /ID# 238458</name>
      <address>
        <city>Lafayette</city>
        <state>California</state>
        <zip>94549-4579</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research /ID# 233497</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles /ID# 239446</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc /ID# 233495</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumos Clinical Research Center /ID# 239018</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124-4108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Management Group /ID# 238503</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786-3676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado /ID# 239838</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers /ID# 240846</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers /ID# 240999</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Denver /ID# 238456</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209-3804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research /ID# 239019</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905-1224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Inst /ID# 238455</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Clinical Research Center /ID# 233335</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials /ID# 233493</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.G.A Clinical Trials /ID# 238409</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute of Miami /ID# 240712</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030-4613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-Speciality Research Associates /ID# 233496</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055-8835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auzmer Research /ID# 241514</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33813-2768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Services, Llc /Id# 238968</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125-5114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biotech Pharmaceutical Group /ID# 239020</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Research Group /ID# 241137</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research /ID# 233535</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida /ID# 240711</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioresearch Institute LLC /ID# 238408</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026-4383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Urgent Care - Pembroke Pines /ID# 241139</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029-2818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Centers - Spring Hill /ID# 231872</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609-5692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Trials - West Broward Outpatient Research Site /ID# 239129</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319-4985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 233420</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 231589</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology PA /ID# 233336</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789-7111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC /ID# 238833</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318-2512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 238852</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328-5574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Georgia Child Neurology /ID# 240845</name>
      <address>
        <city>Brunswick</city>
        <state>Georgia</state>
        <zip>31520-1601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 239832</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research LLC /ID# 231873</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 238454</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Boise /ID# 238978</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of McFarland /ID# 238490</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-5733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College Park Family Care Center Overland Park /ID# 240707</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210-2761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates /ID# 240710</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research (AMR) - Wichita West /ID# 239829</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205-1138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center /ID# 233428</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc. /ID# 233414</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Headache &amp; Neurological Institute (MHNI) /ID# 233492</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104-5131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroBehavioral Medicine Group /ID# 238410</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology - Burnsville /ID# 238828</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337-6732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc /ID# 238411</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402-2606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSync Clinical Research Hattiesburg Clinic /ID# 239837</name>
      <address>
        <city>Petal</city>
        <state>Mississippi</state>
        <zip>39465-2932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Neurology Research Institute /ID# 240974</name>
      <address>
        <city>Ridgeland</city>
        <state>Mississippi</state>
        <zip>39157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharlin Health Neuroscience Research Center /ID# 238969</name>
      <address>
        <city>Ozark</city>
        <state>Missouri</state>
        <zip>65721-5315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials (CCT) - Papillion /ID# 239835</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046-4131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 239441</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060-3483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goryeb Children's Hospital /ID# 239425</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CVS HealthHUB - Runnemede /ID# 240057</name>
      <address>
        <city>Runnemede</city>
        <state>New Jersey</state>
        <zip>08078-1034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center, Inc. /ID# 238415</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioscience Research /ID# 239442</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549-3028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suffolk Neurology /ID# 238457</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776-3387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University /ID# 241140</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CVS HealthHUB - Charlotte /ID# 240842</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC - Charlotte /ID# 238946</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC /ID# 240051</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215-2123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 238461</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Columbus /ID# 238832</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CincyScience /ID# 233334</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 231876</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute (LHSI) /ID# 240705</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research /ID# 231875</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Pediatric Neurology - St. Vincent /ID# 240050</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225-6652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Main /ID# 241138</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC - Scottdale /ID# 239017</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research /ID# 238502</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research - West Ashley A /ID# 240708</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414-5834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research LLC /ID# 239143</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607-4021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Neurology, P.C. /ID# 233419</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Access Clinical Trials, Inc. /ID# 238414</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin /ID# 233427</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759-5290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research - Beaumont /ID# 238407</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77706-3067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Austin /ID# 233406</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613-3513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials /ID# 241141</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Health Research /ID# 233403</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251-2202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3A Research - East El Paso /ID# 241665</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925-7945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Earle Research /ID# 238940</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058-2746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research /ID# 238361</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Trials Worldwide /ID# 238829</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338-3501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMC Science /ID# 240475</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Trials /ID# 233425</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practical Approach Pediatrics /ID# 240840</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research /ID# 238360</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249-3538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of The Woodlands /ID# 238980</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPoint Trials /ID# 238406</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165-1430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research /ID# 240053</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine /ID# 239021</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates LLC/DBA Woodstock Research Center /ID# 240055</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Maria Ona /ID# 239833</name>
      <address>
        <city>Franklin</city>
        <state>Virginia</state>
        <zip>23851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters - Children's Medical Tower /ID# 239142</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research /ID# 238419</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research /ID# 233421</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research - Kingwood /ID# 238459</name>
      <address>
        <city>Kingwood</city>
        <state>West Virginia</state>
        <zip>26537-9797</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Ubrogepant</keyword>
  <keyword>Ubrelvy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

